FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952377498> ?p ?o ?g. }

• W2952377498 abstract "The metabolism of Isoniazid, one of the first-line antituberculosis drugs for TB treatment and prophylaxis, depends on the acetyltransferase 2 acetylation (NAT2) phenotype. Different phenotypes of NAT2 will lead to differences in drug concentration and the risk of uncontrolled side effects, such as hepatitis, peripheral neuropathy, gastrointestinal disorders (nausea, vomiting, and stomach pain). These risks are related to the presence of mutant NAT2 alleles such as NAT2*5 (c.341T> C), *6 (c.590G> A) and *7 (c.857G> A), that reduce the N- acetyltransferase activity. Therefore, the genotyping method for NAT2 polymorphism using RFLP and Sanger sequencing was established. The method was successfully applied to determine the polymorphism of 84 TB patients. This study provides a better tool for analyzing NAT2 gene to assist clinicians in treating isoniazid.&#x0D; Keywords&#x0D; Enzyme NAT2, isoniazid, single nucleotide polymorphism, RFLP, Sanger sequencing.&#x0D; References&#x0D; [1] U.A. Boelsterli, K.K. Lee, Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress, J. Gastroenterol. Hepatol. 29 (2014) 678–687.[2] A. Zabost, S. Brzezinska, M. Kozinska, M. Blachnio, J. Jagodzinski, Z. Zwolska, E. Augustynowicz-Kopec, Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients, Biomed Res Int. 2013 (2013) 1-5.[3] M. Kinzig-Schippers, D. Tomalik-Scharte, A. Jetter, B. Scheidel, V. Jakob, M. Rodamer, I. Cascorbi, O. Doroshyenko, F. Sorgel, U. Fuhr, Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 49 (2005) 1733-8[4] K. Walker, G. Ginsberg, D. Hattis, D.O. Johns, K.Z. Guyton, B. Sonawane, Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity, J Toxicol Environ Health B Crit Rev. 12 (2009) 440-472. [5] G. Ramachandran, S. Swaminathan, Role of pharmacogenomics in the treatment of tuberculosis: a review, Pharmgenomics Pers Med. 5 (2012) 89-98.[6] J. Azuma, M. Ohno, R. Kubota, S. Yokota, T. Nagai, K. Tsuyuguchi, Y. Okuda, T. Takashima, S. Kamimura, Y. Fujio, I. Kawase, Pharmacogenetics-based tuberculosis therapy research group, NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy, Eur J Clin Pharmacol. 69 (2013) 1091-1101.[7] P.S. Adole, P.S. Kharbanda, S. Sharma, N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study, Indian J Med Res. 143 (2016) 581-590.[8] WHO Scientific Group on Pharmacogenetics and World Health Organization, Pharmacogenetics: report of a WHO scientific group,World Health Organization Technical Report Series. (1973)[9] T.D. Da Silva, A.V. Felipe, J.M. De Lima, C.T. Oshima, N.M. Forones, N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer, World J Gastroenterol. 17 (2011) 760-765. [10] E.Y. Lau, J.S. Felton, F.C. Lightstone, Insights into the o-acetylation reaction of hydroxylated heterocyclic amines by human arylamine N-acetyltransferases: a computational study, Chem Res Toxicol. 19 (2006) 182-1190.[11] Ensembl - EBI, http://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=8:18399844-18400844;v=rs1801280;vdb=variation;vf=1243314,2019 (Ensembl release 96 - April 2019).[12] I.B. Kuznetsov, M. McDuffie, R. Moslehi, A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype, Bioinformatics. 25 (2009) 1185-1186. [13] P. Wang, K. Pradhan, X.B. Zhong, X. Ma, Isoniazid metabolism and hepatotoxicity, Acta Pharm Sin B. 6 (2016) 384-392.[14] M. Ohno, I. Yamaguchi, I. Yamamoto, T. Fukuda, S. Yokota, Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity, Int J Tuberc Lung Dis. 4 (2000) 256-261. [15] G.M. Lower, T. Nilsson, C.E. Nelson, H. Wolf, T.E. Gamsky, G.T. Bryan, N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark, Int J Epidemiol. 36 (2007) 11-18.&#x0D; &#x0D; &#x0D;" @default.
• W2952377498 created "2019-06-27" @default.
• W2952377498 creator A5007936696 @default.
• W2952377498 creator A5022047499 @default.
• W2952377498 creator A5031466622 @default.
• W2952377498 creator A5055275359 @default.
• W2952377498 creator A5068083021 @default.
• W2952377498 creator A5066226600 @default.
• W2952377498 date "2019-06-21" @default.
• W2952377498 modified "2023-10-14" @default.
• W2952377498 title "Establishing the Genotyping Method for NAT2 Polymorphism in Vietnamese Tuberculoma Patients" @default.
• W2952377498 doi "https://doi.org/10.25073/2588-1132/vnumps.4137" @default.
• W2952377498 hasPublicationYear "2019" @default.
• W2952377498 type Work @default.
• W2952377498 sameAs 2952377498 @default.
• W2952377498 citedByCount "0" @default.
• W2952377498 crossrefType "journal-article" @default.
• W2952377498 hasAuthorship W2952377498A5007936696 @default.
• W2952377498 hasAuthorship W2952377498A5022047499 @default.
• W2952377498 hasAuthorship W2952377498A5031466622 @default.
• W2952377498 hasAuthorship W2952377498A5055275359 @default.
• W2952377498 hasAuthorship W2952377498A5066226600 @default.
• W2952377498 hasAuthorship W2952377498A5068083021 @default.
• W2952377498 hasBestOaLocation W29523774981 @default.
• W2952377498 hasConcept C104317684 @default.
• W2952377498 hasConcept C135763542 @default.
• W2952377498 hasConcept C142724271 @default.
• W2952377498 hasConcept C168007829 @default.
• W2952377498 hasConcept C2776967927 @default.
• W2952377498 hasConcept C2778328694 @default.
• W2952377498 hasConcept C2781069245 @default.
• W2952377498 hasConcept C31467283 @default.
• W2952377498 hasConcept C501734568 @default.
• W2952377498 hasConcept C54355233 @default.
• W2952377498 hasConcept C71924100 @default.
• W2952377498 hasConcept C76818968 @default.
• W2952377498 hasConcept C86803240 @default.
• W2952377498 hasConceptScore W2952377498C104317684 @default.
• W2952377498 hasConceptScore W2952377498C135763542 @default.
• W2952377498 hasConceptScore W2952377498C142724271 @default.
• W2952377498 hasConceptScore W2952377498C168007829 @default.
• W2952377498 hasConceptScore W2952377498C2776967927 @default.
• W2952377498 hasConceptScore W2952377498C2778328694 @default.
• W2952377498 hasConceptScore W2952377498C2781069245 @default.
• W2952377498 hasConceptScore W2952377498C31467283 @default.
• W2952377498 hasConceptScore W2952377498C501734568 @default.
• W2952377498 hasConceptScore W2952377498C54355233 @default.
• W2952377498 hasConceptScore W2952377498C71924100 @default.
• W2952377498 hasConceptScore W2952377498C76818968 @default.
• W2952377498 hasConceptScore W2952377498C86803240 @default.
• W2952377498 hasIssue "1" @default.
• W2952377498 hasLocation W29523774981 @default.
• W2952377498 hasOpenAccess W2952377498 @default.
• W2952377498 hasPrimaryLocation W29523774981 @default.
• W2952377498 hasRelatedWork W2039709676 @default.
• W2952377498 hasRelatedWork W2106455172 @default.
• W2952377498 hasRelatedWork W2145446924 @default.
• W2952377498 hasRelatedWork W2152541723 @default.
• W2952377498 hasRelatedWork W2158510364 @default.
• W2952377498 hasRelatedWork W2377518790 @default.
• W2952377498 hasRelatedWork W2394359576 @default.
• W2952377498 hasRelatedWork W2403569083 @default.
• W2952377498 hasRelatedWork W2520865132 @default.
• W2952377498 hasRelatedWork W2620504851 @default.
• W2952377498 hasVolume "35" @default.
• W2952377498 isParatext "false" @default.
• W2952377498 isRetracted "false" @default.
• W2952377498 magId "2952377498" @default.
• W2952377498 workType "article" @default.